In:
Gynecologic and Obstetric Investigation, S. Karger AG, Vol. 72, No. 1 ( 2011), p. 50-54
Abstract:
〈 i 〉 Background: 〈 /i 〉 We aimed to determine whether the inclusion of additional cycles of carboplatin-paclitaxel is beneficial to patients with high posttreatment serum CA-125 levels. 〈 i 〉 Methods: 〈 /i 〉 Among patients who achieved remission after six cycles of carboplatin-paclitaxel chemotherapy, those with CA-125 of 10–35 U/ml at the time of remission were divided into two groups (group A: six cycles of standard chemotherapy vs. group B: two or more additional cycles) and were analyzed. 〈 i 〉 Results: 〈 /i 〉 Among the 436 patients with advanced epithelial ovarian cancer, 154 patients (46.8%) had CA-125 of 10–35 U/ml at the time of remission. Fifty-six patients (36.4%) received two or more cycles after the first six cycles of chemotherapy (group B). The addition of two or more cycles of chemotherapy did not improve the progression-free survival (p = 0.660). There was no statistical difference in the rates of CA-125 falling to 〈 10 U/ml between the two groups (p = 0.256). Moreover, the degree of CA-125 decrease after six cycles of chemotherapy was similar regardless of the additional cycles (p = 0.656). 〈 i 〉 Conclusion: 〈 /i 〉 The addition of two or more cycles of standard chemotherapy based on posttreatment CA-125 levels was not beneficial.
Type of Medium:
Online Resource
ISSN:
0378-7346
,
1423-002X
Language:
English
Publisher:
S. Karger AG
Publication Date:
2011
detail.hit.zdb_id:
1482695-1
